Duke logo

MedImmune HCC D4190C00022 for Liver Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether the study drugs Durvalumab, Tremelimumab, and bevacizumab are safe for patients, and whether the study drug regimen can reduce or slow the growth of your cancer.

Additionally, we want to learn what effects, good or bad, the study drugs may have on your body.

What is the Condition Being Studied?

Hepatocellular carcinoma

Who Can Participate in the Study?

Adults who:
- Have never had treatment with drugs similar to durvalumab, tremelimumab, or bevacizumab
- Have a body weight of at least 66 pounds
- Have hepatocellular carcinoma

Age Group

What is Involved?

If you choose to join this study, you will receive a combination of the study drugs durvalumab and bevacizumab until your cancer gets worse or the study doctor decides to take you off the study.

Study Details

Full Title
A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma
Principal Investigator
Protocol Number
Phase II
Contact the Duke Recruitment Innovation Center